You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Under the draft determination, the test would be covered to help assess which treatments to use in patients with advanced prostate cancer.
The final LCD covers AlloSure in renal allograft recipients who have a probability of active renal allograft rejection.
The company announced positive coverage decisions from Palmetto GBA, 14 BCBS plans, and Aetna.
The molecular testing firm estimated that more than 70 percent of Medicare patients with prostate cancer will now have coverage for Prolaris.
The coverage decision limits the test to patients with advanced lung cancers who haven't been genomically profiled and who can't receive tissue-based testing.
S.794 would require Medicare contractors to hold public meetings and disclose the rationale and evidence underlying an LCD at the start of the process.
Several MDx firms recently touted BCBS's Evidence Street opinions on their tests as milestones, and Palmetto GBA's MolDx may soon be using its assessments.
The firm said it expects that Noridian will similarly confirm its draft local coverage determination, bringing coverage for Percepta to around 35 million.
The Medicare contractor is proposing to not cover Vectra DA, but to extend coverage for Prolaris, Xpresys, and DecisionDx-UM under specific circumstances.
Palmetto GBA revised a final LCD for comprehensive genomic profiling in lung cancer, and issued similar draft determinations in other cancers.